|Home | Speakers
| Agenda | Venue | Delegates | Sponsors
| Media | Register
The 2nd Precision Medicine Congress was held on 14-15 September 2015 in London. Thank you to everyone who attended and we are pleased to say the feedback has been very positive.
The meeting is part of our successful Drug Discovery series which includes innovative meetings on Human Microbiome, Synthetic Biology, qPCR / dPCR, Digital Pathology & Biologics among others. www.globalengage.co.uk/events/
Recent advancements in the biomarker, CDx genomic and big data space have meant that some of the fundamental challenges of precision medicine are being realised. The potential for personalized medicine and therefore the possibility of delivering superior outcomes for patients is in reach. There is, however, a lot more to do. Alongside the continued developments in science as well as improvements in clinical trial design, support mechanisms such as market access /reimbursement/ regulatory strategies need to be further developed. Continued work by all stakeholders is therefore vital for success.
The congress was designed for a variety of audiences from drug and DX developers, payers, healthcare providers, academics to technology solution providers.
Attracting experts working in all areas of precision and personalised medicine such as biomarkers, CDx, translational medicine, clinical trials, genomics, NGS, bioinformatics and health economics, this two day interactive meeting provided the opportunity to take home cutting edge strategies, case study examples and methods to allow you to both implement and take the vital next steps in delivering precision medicine. This was achieved through a vibrant exhibition room full of technology providers showcasing their technologies and other solutions, expert led case study presentations and interactive Q&A panel discussions examining topics during four separate tracks covering the areas below.
For a more detailed synopsis or to download last year’s final conference agenda, please visit the agenda page.
further information please contact;